ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
MUC1 promotes NSCLC progression by regulating ICAM-1-mediated mitochondria transfer from tCAFs to cancer cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mitochondrial transfer between tumor and immune cells: a nexus of metabolic adaptation and immune dysfunction.Biomarker research · 2026Review
- Mitochondria transfer: intercellular communication and tumor microenvironment dynamics.Cell communication and signaling : CCS · 2026Review
- Mitochondrial DNA mutations and intercellular mitochondrial transfer in cancer: mechanisms, biological effects, and clinical potential.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated fibroblasts (tCAFs) promote non-small cell lung cancer (NSCLC) progression through cargo exchange with cancer cells. Mucin 1 (MUC1) initiates actin-mediated cytoskeleton protrusion movement to promote mitochondrial transfer. In this study, we aimed to investigate whether MUC1 regulates mitochondrial transfer from tCAFs to NSCLC cells. The results showed that lung cancer patients with high MUC1 expression had a poor prognosis, and MUC1 protein was significantly enriched in exosomes (EXOs) derived from tCAFs. A549 cells were treated with conditioned medium (CM) or EXOs derived from tCAFs or co-cultured with tCAFs in contact or non-contact ways. Both CM and EXOs promoted the proliferation and invasion and inhibited apoptosis in A549 cells, while MUC1-interfered EXOs inhibited A549 cell proliferation and invasion and induced apoptosis. Meanwhile, non-contact co-culture of tCAFs and A549 cells promoted proliferation, invasion, and colony formation of A549 cells, and contact co-culture further promoted malignant phenotype of A549 cells and enhanced mitochondrial function in A549 cells. Mechanism studies revealed that MUC1 promotes mitochondrial transfer from tCAFs to A549 cells by interacting with intercellular adhesion molecule-1 (ICAM1), promoting malignant phenotype of A549 cells. ICAM1 interference counteracted the effect of EXO protein MUC1 on A549 cells. Finally, lung cancer xenograft tumor models were constructed and found that EXO protein MUC1 promoted lung cancer tumor growth in vivo, while ICAM1 interference inhibited tumor growth. In conclusion, MUC1 is enriched in EXOs derived from tCAFs and promotes NSCLC progression by regulating ICAM1-mediated mitochondria transfer from tCAFs to cancer cells.
Indexed as
Identifiers
41105252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.